Impact of Intervention on Reduction of White Blood Cells in the Management of Infection in Pneumonia Patients
DOI:
https://doi.org/10.22270/ajprd.v8i1.642Keywords:
Antibiotic, Pneumonia, WBC, Intervention.Abstract
Objective: To study the impact of intervention on the reduction of white blood cells (WBC) in the management of infection in patients with pneumonia in Universitas Sumatera Utara (USU) hospital period July through September 2019.
Method: This three-month analytical prospective cohort study analyzed the reduction of WBC in the management of infection in pneumonia patients (n=42) before and after intervention in USU hospital. A self-designed questionair was used to assess the patients characterics, the required laboratory data including WBC, and length of stay (LOS). The base-line data were assessed after three days of treatment. The data with intervetion were assessed between July - September 2019. The Patients characteristics and drug utilization were analyzed descriptively. The levels of WBC before and after interventions were compared using paired samples t test (p < 0.05) was considered significant.
Results: Characteristics of the pneumonia patients: male, 61.9%; female, 38.1%. The mean age of patients with pneumonia was 60.48 ± 14.76 years. The most widely used antibiotic was ceftriaxone as much as 48%. There was a significant difference in reduction of WBC between patients with pneumonia before and after intervention, p= 0.002.
Conclusions: Intervention can significantly increase the treatment of infection in patients with pneumonia.
Downloads
References
2. World Health Organization Pneumonia. Factsheets pneumonia. WHO. 2019
3. Loscalzo, J. Harrison's Pulmonary and Critical Care Medicine. New York, United States: McGraw Hill; 2010.
4. National Institutes of Health. Pneumococcal pneumonia. National Institute of Allergy and Infectious Diseases. 2012.
5. Dahlan, Z. Textbook Pathology in vol 2. FKUI. Jakarta. 2001.
6. Minister of Health RI. General Guidelines for the Utilization of Antibiotics. PMK RI No.2406/MENKES/PER/XII/2011:2011.
7. World Health Organization, Rational use of medicines, Fact sheet N°338 May 2010. Available from: http://www.who.int/mediacentre/factsheets/ fs338/en, accessed on October 22nd 2017.
8. Dahlan, Z. Amin, Z., Soeroto, A., Y. Compendium Respirology and management of critical respiration. Jakarta: Respirology Association of Indonesia; 2011.
9. IRIN. Antibiotic use "excessive", say specialists. Report/92475/INDONESIA-Antibioticuse-excessive-say-specialists. 2011.
10. Minister of Health RI). Decree of the Minister of Health of the Republic of Indonesia Number Republik Indonesia Nomor 1197/Menkes/Sk/X/2004. About Standards of Pharmacy Services in Hospitals. Jakarta. 2004
11. Dipiro JT. Encyclopedia of clinical pharmacy. New York. 2003.
12. Ohls, R., K., Christensen, R., D. Development of the hematopoietic system. In: Kliegman, Behrman, Jenson, edsStaton. Nelson Textbook of Pediatrics. 18th ed. Philadelphia: Saunders Elsevier; 2017
13. Kothe H, Bauer, T., Marre, R., Suttorp, N., Welte, T., Dalhoff, K. Outcome of community-acquired pneumonia: Influence of age, residence status and antimicrobial treatment. European Respiratory Journal, 2008; 32(1):139-146.
14. High, K. Evaluation of Infection in the Older Adult. New York. 2015.
15. Menendez, R., Ferrando, D., Valles, JM, Martinez, E., Perpina, M. Initial risk class and length of hospital stay in community-acquired pneumonia. European Respiratory Journal. 2001; 18:151-156.
16. Brunton L., Keuth, P., Dinald, B., Iain, B. Goodman & Gilman: A Manual of Pharmacology and Therapeutics. Translation: Sukanda YE, Book Medical Publishers EGC, Jakarta. 2008; 671 – 680:687-710, 727-734
17. Indonesian Lung Doctors Association. Community Pneumonia. Practical Guidelines for Diagnosis and Management in Indonesia. Jakarta: FKUI Publisher Institute; 2014. p. 1-52.
18. Neal, Michael J. Medical Pharmacology at a Glance, Ed. 7th. Great Britain : MPG Books Ltd; 2012:80-85.
19. Deck, Daniel H. and Winston, Lisa G.Tetracyclines, Macrolides, Clindamycin, Chloramphenicol, Streptogramins, & Oxazolidinones. In: Katzung, Bertram G., Masters, Susan B., and Trevor, Anthony J. (Eds.). Basic and Clinical Pharmacology, 13th Ed. New York : McGraw-Hill; 2015. p. 788-798.
20. Petri, William A. And Jr.Penicillins, Cephalosporins, and other β- lactam Antibiotics. In: Brunton, L., Chabner, B., and Knollman, B. (Eds.). Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 12th Ed. New York: Mc Graw Hill; 2011.
21. McEvoy, Gerald K. AHFS Drug Information Essentials: Point-of- Care Drug Information for Health Care Professionals. Bethesda: American Society of Health-System Pharmacists Inc; 2011.
22. Fish, D. N., and Chow, A. T. The Clinical Pharmacokinetics of Levofloxacin. Adis International limited; 2005; 101-119.
23. Mathieu B, Delphine C, André P, Ameline V. A Leukocyte Score to Improve Clinical Outcome Predictions in Bacteremic Pneumococcal Pneumonia in Adults. PMCID: PMC4281790. 10.1093/ofid/ofu075: 2014
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.